Hardman & Co recently welcomed Milan Radia to our roster of established, industry expert analysts. Milan has 25 years of equity market experience at major investment banks and in asset management, and has worked on many high-profile successful IPOs. In 2017, he was ranked the No.1 earnings estimator in the UK for his sector in the Thomson Starmine Awards. Milan has also been techMARK Analyst of the Year and achieved top three Institutional Investor sector rankings for his coverage of the software and telecoms sectors. In our lead article this month he gives an insight into his thinking on some key themes in the sector.

04 Jun 2018
The Monthly
Time Finance plc (TIME:LON), 56.0 | Abzena (ABZA:LON), 0 | Allergy Therapeutics plc (AGY:LON), 6.8 | Alliance Pharma plc (APH:LON), 64.6 | Arbuthnot Banking Group PLC (ARBB:LON), 932 | Avacta Group PLC (AVCT:LON), 34.5 | Burford Capital Limited (BUR:LON), 1,033 | City of London Investment Group PLC (CLIG:LON), 370 | TheraCryf PLC (TCF:LON), 0.2 | Gateley (Holdings) Plc (GTLY:LON), 130 | Genedrive Plc (GDR:LON), 1.5 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Primary Health Properties PLC (PHP:LON), 103 | R.E.A. Holdings plc (RE:LON), 72.8 | Scancell Holdings Plc (SCLP:LON), 10.0 | Surface Transforms PLC (SCE:LON), 0.5 | Tissue Regenix Group plc (TRX:LON), 32.5 | Titon Holdings Plc (TON:LON), 67.5 | Oxford BioMedica plc (OXB:LON), 295 | ValiRx PLC (VAL:LON), 0.6

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
The Monthly
Time Finance plc (TIME:LON), 56.0 | Abzena (ABZA:LON), 0 | Allergy Therapeutics plc (AGY:LON), 6.8 | Alliance Pharma plc (APH:LON), 64.6 | Arbuthnot Banking Group PLC (ARBB:LON), 932 | Avacta Group PLC (AVCT:LON), 34.5 | Burford Capital Limited (BUR:LON), 1,033 | City of London Investment Group PLC (CLIG:LON), 370 | TheraCryf PLC (TCF:LON), 0.2 | Gateley (Holdings) Plc (GTLY:LON), 130 | Genedrive Plc (GDR:LON), 1.5 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Primary Health Properties PLC (PHP:LON), 103 | R.E.A. Holdings plc (RE:LON), 72.8 | Scancell Holdings Plc (SCLP:LON), 10.0 | Surface Transforms PLC (SCE:LON), 0.5 | Tissue Regenix Group plc (TRX:LON), 32.5 | Titon Holdings Plc (TON:LON), 67.5 | Oxford BioMedica plc (OXB:LON), 295 | ValiRx PLC (VAL:LON), 0.6
- Published:
04 Jun 2018 -
Author:
Mark Thomas -
Pages:
44 -
Hardman & Co recently welcomed Milan Radia to our roster of established, industry expert analysts. Milan has 25 years of equity market experience at major investment banks and in asset management, and has worked on many high-profile successful IPOs. In 2017, he was ranked the No.1 earnings estimator in the UK for his sector in the Thomson Starmine Awards. Milan has also been techMARK Analyst of the Year and achieved top three Institutional Investor sector rankings for his coverage of the software and telecoms sectors. In our lead article this month he gives an insight into his thinking on some key themes in the sector.